UBS Upgrades Intuitive Surgical Stock Amid Market Selloff
On July 28, 2026, UBS upgraded its rating on Intuitive Surgical (ISRG) to Buy from Neutral following a significant year-to-date decline in the stock. The firm set a new 12-month price target of $500 and argued that the recent selloff was overblown. UBS challenged prevailing concerns about slowing growth, hospital spending cuts, and rising competition by emphasizing its belief in automation's role in accelerating robotic surgery adoption. It also highlighted potential revenue expansion into cardiac procedures, endoluminal applications, and lung biopsy platforms as key drivers for future growth. Despite reporting strong second-quarter results with 19% year-over-year revenue growth and beating expectations on both earnings and revenue, the stock fell over 12%. UBS attributed this to an overreaction by investors focusing narrowly on a slowdown in U.S. procedure growth.
Tickers: $ISRG
Topics: healthcare stocks Intuitive Surgical stock upgrade UBS